The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"In conclusion, as insight is gained into the clinical phenotypes associated with COVID-19, we propose JAK and IL-1 inhibitors as therapeutic targets warranting rapid investigation" thelancet.com/journals/lanre…
Sareum $SAR.L #TYK2 #AIM #biotech #Covid-19
Presentation on Sareum website.....
Diseases such as Covid-19, SARS, MERS, influenza etc. can be fatal due to a “cytokine storm” overreaction of the immune system
• Key cytokines elevated in Covid-19 ICU patients are reported to include:
• IL-2, IL-7, IL-10, G-CSF – all signal via JAK-family kinases
• Clinical trials of JAK-family inhibitors ruxolitinib, tofacitinib, baricitinib in Covid-19 patients are in progress or planned
• Secondary bacterial infections induce IL-1ß and GM-CSF
• GM-CSF reported to improve outcome in patients with pneumonia-associated ARDS
• IL-1ß - GM-CSF pathway blocked by virally-induced IFNa and IFN?
• TYK2/JAK1 inhibition blocks IFNa/? signalling and thus restores GM-CSF levels
• GM-CSF signals via JAK2
• Suggests a TYK2/JAK1 inhibitor that does not inhibit JAK2 to be optimally beneficial
• Sareum’s SDC-1801/2 inhibit TYK2 and JAK1, but not JAK2
Should be interesting today....
The presentation will provide an update of Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively. Dr Mitchell will also highlight the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections.
Hi Del77, still here mate in the background from 2008. Still hold a few million as believe in the company, but not really had the time to post. I do appreciate the posts as some really knowledgeable posters with good research. Still awaiting the 10p party
Thanks Del77, appreciate your post. I think I�m in my ninth year here and even more confident than ever and long overdue. Work keeping me from posting much over the last few years but still have the faith and leave it to many knowledgeable posters to keep everyone informed. Hope you get your price over the coming months and good luck
Brief details as requested by NewForestLad......... Sareum The company is talking about 2-3 deals with one expected by the year end. The first deal is now due in January and appears from feedback from the AGM in December it’s just a matter of a signature. They have CHK1 in a joint collaboration with ICR and CRT where it is equally shared and from the broker note it could bode very well and be a blockbuster with possible sales of 1 billion if it passes through the clinical trials. Sareum do not believe in being the first to market but “Best In Class” and they have been working on this compound for 5-6 years now and should be transformational for SAR with their share alone. The program that excites me the most is Aurora/FLT3 which is 100% owned and caused the initially spike in Feb 2011 when it released that it had performed with 10 out of 10 success in pre-clinical trials. Sareum have multiple programs CHK1, Aurora, FLT3, VEGFR, TYK2, ALK, Microtubule Binding, FASN, PLK1 and Braf and all 100% owned with the exception of CHK1. They have recently indicated that they need to find more programs from their 100% owned SKIL platform and this is because it is believed that the three deals will tie up co-development, sponsorship and ownership of the majority of the current programs. Couple of links below for your review: http://www.sareum.co.uk/pressreleases.php?newsid=144&year=2011 http://www.sareum.co.uk/pressreleases.php?newsid=162&year=2012 http://www.sareum.co.uk/pressreleases.php?newsid=170&year=2012 http://www.sareum.co.uk/base/images/pdfs/SareumJuly192012.pdf Feel free to ask any questions on the SAR BB……Good luck all
link to RNS http://www.investegate.co.uk/Article.aspx?id=201107080700090078K